Ovarian Neoplasms: all 2,759 studies

Page 13 of 28. Open to participants first (736), then studies with results posted, then the rest; newest registration first within each.

• Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer TreatmentCompletedNCT06870539
• Regional Distribution Mapping of Lymph Node Metastasis in Epithelial Ovarian CancerCompletedNCT06853730
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903CompletedNCT06846099Phase 1
• Role of Hysterectomy in the Treatment of Borderline Ovarian TumorsCompletedNCT06825468
• The Impact of the Inflammation Index on Predicting Postoperative Complications in Ovarian CancerCompletedNCT06798610
• XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Active, not recruitingNCT06792435Phase 1/2
• Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian CancerCompletedNCT06787170
• Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsActive, not recruitingNCT06781983Phase 1
• A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109 in Patients With Colorectal, Ovarian, and Renal CancersTerminatedNCT06760702Phase 2
• Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid TumorsTerminatedNCT06714617Phase 1
• Development and Validation of a Prediction Model for AKI Following Cisplatin-Based HIPEC in Patients With Ovarian CancerCompletedNCT06697613
• A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese PatientsActive, not recruitingNCT06682572Phase 2
• Helping Ovarian Cancer Patients Cope With Their Illness (HOPE)SuspendedNCT06666218Not applicable
• GYNecologic Cancer-Related COGnitive ImpairmentCompletedNCT06662435Not applicable
• Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian CancerCompletedNCT06660147
• Systemic Inflammatory Biomarkers in Ovarian CancerCompletedNCT06629831
• Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian CancerCompletedNCT06624878Not applicable
• Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerActive, not recruitingNCT06619236Phase 3
• Dose-Escalation of MNPR-101-PCTA-177Lu in Solid TumorsActive, not recruitingNCT06617169Phase 1
• Improved Early Diagnosis in Female Pelvic Cancer With OC DetectCompletedNCT06613230
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsActive, not recruitingNCT06607185Phase 1
• Enhanced Assistance During Radiotherapy for Unmet Essential NeedsCompletedNCT06582849Not applicable
• A Study of SGN-B6A in Chinese Participants With Advanced Solid TumorsCompletedNCT06549816Phase 1
• A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.TerminatedNCT06546553Phase 1
• A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid TumorsActive, not recruitingNCT06533059Phase 1
• Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated HypertensionActive, not recruitingNCT06515678
• A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY TrialActive, not recruitingNCT06497270Not applicable
• Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)Active, not recruitingNCT06494150Phase 2
• Diet, Hepcidin, and Chemotherapy RDIActive, not recruitingNCT06483997
• A Biomarker Exploration Study of Precision Treatment in Ovarian CancerActive, not recruitingNCT06483425
• Research on Nutritional Risk Indexes and Inflammatory Indicators in Postoperative Complications and Prognosis of Epithelial Ovarian Cancer PatientsCompletedNCT06483399
• Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After TherapyTerminatedNCT06478862Phase 2
• An Exploratory Clinical Study of Statins for Improving Chemotherapy and Maintenance in Patients With Ovarian CancerStatus unknownNCT06468254Phase 2
• A Study of SGN-MesoC2 in Advanced Solid TumorsTerminatedNCT06466187Phase 1
• Identification of Risk Factors and Construction of Prediction Model for Postoperative Intestinal Anastomotic Leakage in Ovarian CancerCompletedNCT06458361
• A Study of PHN-010 in Patients With Advanced Solid TumorsTerminatedNCT06457997Phase 1
• Nudge to Gynecologic OncologyActive, not recruitingNCT06451263Not applicable
• Polygenic Risk Scores and Multi-cancer Early Detection for Ovarian CancerActive, not recruitingNCT06436248
• Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)CompletedNCT06433219Phase 2
• M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)Active, not recruitingNCT06421935Phase 1
• Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACTActive, not recruitingNCT06412510Phase 1/2
• (GI-RADS) in Preoperative Evaluation of Adnexal MassesCompletedNCT06403072
• A Study to Investigate APL-5125 in Adults With Advanced Solid TumorsCompletedNCT06399757Phase 1
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1CompletedNCT06386653Phase 1
• Systematic Lymphadenectomy During Interval Debulking Surgery in Advanced Epithelial Ovarian CancerCompletedNCT06385912
• Study of ACE-86225106 to Treat Patients With Advanced Solid TumorsActive, not recruitingNCT06380660Phase 1/2
• The Efficacy of WeChat-based Multidisciplinary Full-course Nutritional Management ProgramCompletedNCT06379191Not applicable
• A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung CancersTerminatedNCT06376253Phase 1
• Diagnosis of Epithelial Ovarian Cancer Using Ovarian Cancer Score (OCS) TestCompletedNCT06366997
• A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha ExpressionActive, not recruitingNCT06365853Phase 2
• Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal CancerActive, not recruitingNCT06342986Phase 1
• ASk Questions in GYnecologic Oncology (ASQ-GYO)CompletedNCT06339827Not applicable
• Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid TumorsActive, not recruitingNCT06337084Phase 1
• A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid TumorsTerminatedNCT06336148Phase 1
• Erdafitinib in Metastatic Steroid-cell Ovarian CancerCompletedNCT06328491Not applicable
• Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World SettingCompletedNCT06324734
• The Epigenetic Regulatory Role of P-element Induced Wimpy Testis (Piwi) Interacting RNA-823 (piR-823) in Ovarian Cancer ProgressionActive, not recruitingNCT06320418
• A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian CancerTerminatedNCT06315491Phase 2
• NM32-2668 in Adult Patients With Selected Advanced Solid TumorsTerminatedNCT06299163Phase 1
• A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid TumorsTerminatedNCT06285097Phase 1
• A Study With NKT3447 for Adults With Advanced/Metastatic Solid TumorsTerminatedNCT06264921Phase 1
• A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid TumorsTerminatedNCT06257758Phase 1/2
• A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Phase 1
• Luspatercept in Metastatic AGCT of the OvaryCompletedNCT06254781Not applicable
• Clinical and Pathological Characteristics of Women With Ovarian Cancers in SyriaCompletedNCT06253559
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• A Study of Second Look Laparoscopy (SLL) in People With Ovarian Cancer Who Have Completed Their First Course of ChemotherapyActive, not recruitingNCT06240598Phase 2
• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
• Inferior Epigastric Lymp Node (IELN) Basin as a Possible Systemic Metastatic Pathway of Ovarian Peritoneal MetastasesCompletedNCT06237582Not applicable
• Intraperitoneal LSTA1 in CRS-HIPECWithdrawnNCT06216561Phase 1
• Single-port Laparoscopy in Children and AdolescentsCompletedNCT06201221
• Choices About Genetic Testing And Learning Your Risk With Smart TechnologyCompletedNCT06184867Not applicable
• PRO1107 in Patients With Advanced Solid TumorsTerminatedNCT06171789Phase 1/2
• Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - ItalyCompletedNCT06161233Not applicable
• The Effectiveness of an Online Support Group in Enhancing Recovery Identity and Health-Related Quality of LifeCompletedNCT06145295Not applicable
• Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination DeficiencyWithdrawnNCT06120972Phase 2
• New Prognostic Index for Neoadjuvant Chemotherapy Outcome in Patients With Advanced High-grade Serous Ovarian CancerStatus unknownNCT06120309
• Study of DF6215 in Patients With Advanced Solid TumorsCompletedNCT06108479Phase 1
• Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine CancerActive, not recruitingNCT06107868Phase 1
• The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological SurgeryCompletedNCT06103214Not applicable
• A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT06087289Phase 1/2
• Association of Ex Vivo Drug Response (EVDR) and Clinical Outcome in Ovarian CancerTerminatedNCT06068738
• Ovarian Tumor Organotypic Slices Cultures for functionAl Drug Testing and Therapy Response PredictionActive, not recruitingNCT06065358Not applicable
• Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid TumorsTerminatedNCT06065059Phase 1/2
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesTerminatedNCT06052852Phase 1
• Clinical Effect Evaluation of Laparoscopic Surgery for Ovarian Benign Tumors by Different ApproachesCompletedNCT06047730
• A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer PatientsActive, not recruitingNCT06028932Phase 2
• Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor PatientsCompletedNCT06007586Phase 3
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2Active, not recruitingNCT06003231Phase 2
• A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid TumorsActive, not recruitingNCT05973487Phase 1
• First-in-human Interleukin-15-transpresenting Wilms' Tumor Protein 1-targeting Autologous Dendritic Cell Vaccination in Cancer PatientsCompletedNCT05964361Phase 1/2
• Comparison of Weekly Versus Every Three Weeks of Carboplatin Plus Paclitaxel in Patients With Advanced Epithelial Ovarian CancerCompletedNCT05963334Phase 1/2
• Proteogenomic Signatures Analysis In Ovarian CancerActive, not recruitingNCT05953883Not applicable
• Interventions to Decrease Financial ToxicityCompletedNCT05939440Not applicable
• Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic CancerActive, not recruitingNCT05922930Phase 1/2
• Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerActive, not recruitingNCT05920798Phase 1/2
• A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian FederationCompletedNCT05918042
• Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 MutationsCompletedNCT05904730Phase 1
• [68Ga]Ga-FAPI-46 PET/CT in Ovarian CancerTerminatedNCT05903807Phase 2

← Ovarian Neoplasms overview